Sign in
CompletedNo phase

Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease

Key facts

Who runs it
Tungs' Taichung Metroharbour Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
155 people enrolled
Started
3 May 2023
Ended
31 Dec 2023
Type of study
Observational
Record updated
1 March 2024

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • A cohort of aged 20 or over, who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month

Who cannot take part

  • We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background

Read full original descriptionShow less

Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. A cross-sectional study will be carried out the evaluate the possible association endotoxin core antibody with asymptomatic PAD in a cohort of HD patients.

Methods

This cohort study enrolled 500 HD patients treated at a single center in Taichung city. Fasting blood samples will be collected to determine biochemical data Endotoxin core antibody levels and other related biomarkers. By the automatic oscillometric method, the ankle-brachial index (ABI) was measured. Low ABI was defined as any value < 0.9.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 March 2024